An Adaptive, Randomized, Double-blinded, Placebo-controlled, Phase II/III Trial of Monoclonal Antibody SCTA01 Against SARS-CoV-2 in Patients With Severe COVID-19 Admitted to High Dependence or Intensive Care Unit (MASP3 Trial)
Latest Information Update: 06 Dec 2022
At a glance
- Drugs Upanovimab (Primary)
- Indications COVID 2019 infections
- Focus Registrational; Therapeutic Use
- Acronyms MASP3 Trial
- Sponsors Sinocelltech
- 29 Dec 2020 New trial record